Table 3 Univariable and multivariable analysis for overall survival in patients with mHSPC treated with ADT
Multivariable | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Univariable | Model I (Base line PSA adjusted) (n = 52; chi-square 26.5; AIC 122.9) | Model II (n = 52; chi-square 22.8; AIC 121.1) | ||||||||
Factors | Group | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value |
Age | Continuous | 1.01 | 0.96–1.07 | 0.702 | ||||||
ECOG-PS | 1 vs 0 | 1.10 | 0.26–4.76 | 0.895 | ||||||
Log-transformed baseline PSA level (ng/dL) | Continuous | 0.81 | 0.67–0.99 | 0.035 | 1.25 | 0.58–2.71 | 0.572 | |||
Baseline Hb level(g/dl) | Low vs normal | 1.90 | 0.85–4.27 | 0.120 | ||||||
Baseline ALP level (IU/l) | High vs normal | 1.34 | 0.60–3.02 | 0.480 | ||||||
Baseline LDH level (IU/l) | High vs normal | 1.08 | 0.48–2.43 | 0.846 | ||||||
Presence of bone pain | Yes vs No | 2.23 | 1.00–4.98 | 0.049 | ||||||
Biopsy Gleason score | ≥8 vs ≤7 | 0.55 | 0.16–1.89 | 0.345 | ||||||
Visceral metastasis | Yes vs No | 5.37 | 1.18–24.32 | 0.029 | ||||||
EOD score | ≥3 vs ≤2 | 3.85 | 1.55–9.59 | 0.004 | 1.97 | 0.61–6.39 | 0.256 | 2.05 | 0.65–6.46 | 0.222 |
Sub-group in the CHAARTED trial | high vs low | 2.03 | 0.86–4.82 | 0.109 | ||||||
Log-transformed PSA change (baseline-12wks) | Continuous | 0.78 | 0.64–0.95 | 0.014 | 0.55 | 0.26–1.18 | 0.123 | 0.68 | 0.54–0.85 | 0.001 |
Hb level at 12 weeks | Low vs normal | 2.44 | 1.12–5.31 | 0.025 | 2.54 | 0.92–7.00 | 0.071 | 2.58 | 0.95–7.04 | 0.060 |
ALP level at 12 weeks | High vs normal | 3.47 | 1.59–7.58 | 0.002 | 3.37 | 1.01–11.23 | 0.048 | 3.57 | 1.11–11.53 | 0.030 |
LDH level at 12 weeks | High vs normal | 1.74 | 0.75–4.00 | 0.197 | ||||||